We describe two patients with EIF2AK4-associated PAH alive 2 and 10 years after diagnosis who both demonstrate an underreported feature potentially unique to their favourable clinical trajectory corroborated by near normalization of pulmonary vascular resistance and preserved WHO functional class following pulmonary vasodilator treatment. Here, EIF2AK4 is linked to pulmonary arterial hypertension.